KDR and hepatocellular carcinoma: In the last few years, some of the FDA-approved VEGFR-2 inhibitors, including sorafenib (I), regorafenib (II), lenvatinib (III), nintedanib (IV), sunitinib (V) and pazopanib (VI), were employed for clinical studies either alone or in combination with some other chemotherapies for the treatment of HCC [36].